Starling Oncology, Inc. (NASDAQ: STLN) is a Healthcare company (Medical - Care Facilities) with a market capitalization of $347M. The Maz Rating grades it against the other companies in its sector.
Starling Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.40, Starling Oncology, Inc. trades at 0.6x sales. Over the last twelve months it generated about $617M of revenue and a net loss of $29M. It runs a gross margin of 16.5%, an operating margin of -3.3% and a net margin of -5.7%. It shows return on equity of 150.8%, return on invested capital of -28.3% and a free cash flow yield of 5.4%. On the balance sheet: a debt-to-equity ratio of -2.62 and a current ratio of 1.11. Over the past 52 weeks the share price ranged from $2.32 to $7.13, with a beta of 0.42.
Starling Oncology, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.